ES519423A0 - Procedimiento para preparar 9-(1 o 3-monoaciloxi-o 1,3-diaciloxi-2-propoximetil)-purinas substituidas en calidad de agentes antiviricos. - Google Patents

Procedimiento para preparar 9-(1 o 3-monoaciloxi-o 1,3-diaciloxi-2-propoximetil)-purinas substituidas en calidad de agentes antiviricos.

Info

Publication number
ES519423A0
ES519423A0 ES519423A ES519423A ES519423A0 ES 519423 A0 ES519423 A0 ES 519423A0 ES 519423 A ES519423 A ES 519423A ES 519423 A ES519423 A ES 519423A ES 519423 A0 ES519423 A0 ES 519423A0
Authority
ES
Spain
Prior art keywords
propoximetil
monoaciloxi
diaciloxi
antiviric
purins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES519423A
Other languages
English (en)
Other versions
ES8504194A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of ES519423A0 publication Critical patent/ES519423A0/es
Publication of ES8504194A1 publication Critical patent/ES8504194A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1786—Unsaturated ethers containing hydroxy or O-metal groups containing halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES519423A 1982-02-01 1983-01-31 Procedimiento para preparar 9-(1 o 3-monoaciloxi-o 1,3-diaciloxi-2-propoximetil)-purinas substituidas en calidad de agentes antiviricos. Expired ES8504194A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34470382A 1982-02-01 1982-02-01
US07/451,262 US5250535A (en) 1982-02-01 1982-12-22 Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent

Publications (2)

Publication Number Publication Date
ES519423A0 true ES519423A0 (es) 1985-04-16
ES8504194A1 ES8504194A1 (es) 1985-04-16

Family

ID=26994067

Family Applications (1)

Application Number Title Priority Date Filing Date
ES519423A Expired ES8504194A1 (es) 1982-02-01 1983-01-31 Procedimiento para preparar 9-(1 o 3-monoaciloxi-o 1,3-diaciloxi-2-propoximetil)-purinas substituidas en calidad de agentes antiviricos.

Country Status (20)

Country Link
US (1) US5250535A (es)
EP (1) EP0085424A3 (es)
KR (1) KR890000191B1 (es)
AU (2) AU572777B2 (es)
BR (1) BR8300475A (es)
DD (1) DD206781A5 (es)
DK (1) DK29183A (es)
ES (1) ES8504194A1 (es)
FI (1) FI79851C (es)
GR (1) GR81321B (es)
HU (1) HU193874B (es)
IL (1) IL67791A0 (es)
IN (1) IN157856B (es)
NO (1) NO161372C (es)
NZ (1) NZ203128A (es)
PH (5) PH19203A (es)
PL (1) PL140556B1 (es)
PT (1) PT76149B (es)
RO (3) RO86234B (es)
ZW (1) ZW2583A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3278501D1 (en) * 1981-08-11 1988-06-23 Wellcome Found Antiviral compounds
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds
US4544634A (en) * 1982-10-14 1985-10-01 Burroughs Wellcome Co. Method of producing acyclovir
US4609662A (en) * 1982-10-14 1986-09-02 Burroughs Wellcome Co. Method for using purine derivatives
NO161116C (no) * 1982-10-14 1989-07-05 Wellcome Found Analogifremgangsmaate for fremstilling av antiviralt virksomme purinderivater.
US4880820A (en) * 1983-06-24 1989-11-14 Merck & Co., Inc. Guanine derivatives
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
EP0138683A3 (en) * 1983-09-30 1988-01-20 Merck & Co. Inc. Purine derivatives, their application in anti-viral compositions
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
DE3571810D1 (en) * 1984-01-26 1989-08-31 Merck & Co Inc Substituted butyl guanines and their utilization in antiviral compositions
US4579849A (en) * 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
EP0190123A1 (en) * 1984-07-20 1986-08-13 GAUNTT, Charles, O. Immunoregulatory and anti-viral compound
FI91959C (fi) * 1984-12-12 1994-09-12 Syntex Inc Menetelmä valmistaa alkoksimetyylieetteri- ja alkoksimetyyliesterijohdoksia
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
DE3627024A1 (de) * 1985-09-24 1987-04-02 Hoechst Ag In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
US4966895A (en) * 1989-02-02 1990-10-30 Merck & Co. Inc. Cyclic monophosphates of purine and pyrimidine acyclonucleosides as anti-retroviral agents
US5216142A (en) * 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5565565A (en) * 1994-08-04 1996-10-15 Syntex (U.S.A.) Inc. Preparation of N-9 substituted guanine compounds
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4347360A (en) * 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
DE3278501D1 (en) * 1981-08-11 1988-06-23 Wellcome Found Antiviral compounds
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds
NZ201662A (en) * 1981-08-26 1986-07-11 Merck & Co Inc 9-(1,3-(and 2,3)-dihydroxy-1-(and 2)-propoxy-methyl)guanine derivatives and methods for their preparation

Also Published As

Publication number Publication date
KR840003253A (ko) 1984-08-20
EP0085424A2 (en) 1983-08-10
PL240367A1 (en) 1985-10-08
RO86234B (ro) 1985-03-31
IN157856B (es) 1986-07-12
RO86234A (ro) 1985-03-15
PL140556B1 (en) 1987-05-30
PH19203A (en) 1986-01-31
BR8300475A (pt) 1983-11-01
US5250535A (en) 1993-10-05
PH22824A (en) 1989-01-19
HU193874B (en) 1987-12-28
GR81321B (es) 1984-12-11
PT76149B (en) 1985-11-25
DK29183D0 (da) 1983-01-25
DK29183A (da) 1983-08-02
DD206781A5 (de) 1984-02-08
ZW2583A1 (en) 1983-05-11
RO89143A (ro) 1986-04-30
ES8504194A1 (es) 1985-04-16
PT76149A (en) 1983-02-01
PH20099A (en) 1986-09-24
NO161372B (no) 1989-05-02
PH20360A (en) 1986-12-04
PH22817A (en) 1989-01-19
FI830254A0 (fi) 1983-01-26
FI830254L (fi) 1983-08-02
IL67791A0 (en) 1983-05-15
AU1096183A (en) 1983-08-11
AU572777B2 (en) 1988-05-19
KR890000191B1 (ko) 1989-03-10
AU1261488A (en) 1988-06-02
NZ203128A (en) 1987-08-31
FI79851C (fi) 1990-03-12
RO89142A (ro) 1986-04-30
NO161372C (no) 1989-08-09
FI79851B (fi) 1989-11-30
EP0085424A3 (en) 1984-07-18
NO830316L (no) 1983-08-02

Similar Documents

Publication Publication Date Title
ES519423A0 (es) Procedimiento para preparar 9-(1 o 3-monoaciloxi-o 1,3-diaciloxi-2-propoximetil)-purinas substituidas en calidad de agentes antiviricos.
ES520195A0 (es) Procedimiento para preparar nuevos derivados de 3-ceto- 4,9,19-nor-esteroides.
ES521139A0 (es) Procedimiento para preparar poliester-alcoholes o poliester-polioles.
ES519367A0 (es) Procedimiento para preparar derivados de ciclohexano-1,3-diona.
ES520957A0 (es) Procedimiento para preparar composiciones herbicidas.
ES516275A0 (es) Procedimiento para preparar 1,2-dihidroxi-ciclohexadienos.
ES529728A0 (es) Procedimiento para preparar amino-2-fenil-5-benzodiazepinas-1, 3
ES523064A0 (es) Procedimiento para preparar azetidinas.
ES519709A0 (es) Procedimiento para preparar derivados de ciclohexeno-1,2-diona 5-aril-sustituidos.
ES520273A0 (es) Procedimiento para la obtencion de trimetilolpropano.
ES520812A0 (es) Procedimiento para la preparacion de 3-azolil-1,2-diaril-1-halogeno-1-propenos.
ES521458A0 (es) Procedimiento para preparar colorantes diazoicos.
ES501245A0 (es) Procedimiento para la preparacion de -aminocarbonil-1-ben- cil-3,4-dihidro-isoquinoleinas
ES521813A0 (es) Procedimiento para preparar alcohil-polisacaridos.
ES525186A0 (es) Procedimiento para preparar nuevas imidazo-(1,2-a)-pirimidinas
ES527945A0 (es) Procedimiento para preparar derivados de bencilcarbamoilpiridina.
ES520531A0 (es) Procedimiento para preparar tioeteres.
ES523243A0 (es) "procedimiento para preparar derivados de 1,4-dihidropiridina".
ES525333A0 (es) Procedimiento para preparar derivados de sulfamoilbenzofenona.
ES522474A0 (es) Procedimiento para la obtencion de halogenopropargilformamidas.
ES519366A0 (es) Procedimiento para preparar derivados de ciclohexano-1,3-diona-5-fenil-sustituidos.
ES532109A0 (es) Procedimiento para preparar 9-(1 o 3-monoaciloxi-o 1,3-diaciloxi-2-propoximetil)-purinas substituidas en calidad de agentes antiviricos.
ES520847A0 (es) Procedimiento para la preparacion de 1,2,4-triazol-1-il-propionitrilos.
ES520201A0 (es) Procedimiento para la obtencion de derivados de 1,4-dihidropiridina.
ES520624A0 (es) Un procedimiento para la preparacion de derivados de 3-cxa-1-azabiciclo (4,2,0) octano.